ArticleCureus2025
Monitoring and Management of Uric Acid Therapy in Gout and Chronic Kidney Disease: A Single-Center Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Gout commonly coexists with chronic kidney disease (CKD) due to reduced renal excretion of uric acid (UA). Guidelines recommend regular monitoring and dose adjustment of urate-lowering therapy (ULT), but the rate of adherence to these guidelines is not well established. Our study aimed to determine adherence to ULT guidelines in gout patients at our institution. In particular, we sought to assess the effect of CKD as well as other comorbidities on the prevalence of ULT guideline adherence. Methods We conducted a retrospective cohort study of 5,985 gout patients at our institution initiated on allopurinol between 2015 and 2020. Inclusion criteria were age over 18, a gout diagnosis, and a new allopurinol prescription. The primary outcome was UA monitoring within six months of therapy initiation. A secondary outcome was the prevalence of dose adjustments made by providers in response to a UA level above target. Results Only 48.3% (n = 2,889) of patients had UA levels monitored within six months. CKD stage did not significantly impact monitoring rates (p = 0.059). In patients with elevated UA levels (>6 mg/dL), 54.3% (n = 1,011) of patients had no dosage adjustments. Conclusions Significant gaps exist in adherence to ULT guidelines; nearly half of patients did not undergo recommended UA monitoring. Over half of patients with elevated uric levels did not have dosage adjustments. CKD stage did not affect the likelihood of UA monitoring or dose changes in persons with elevated UA levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.